The Providence Thoracic Surgery Initiative endorses a position against performing routine mutation analysis of lung cancer pathology specimens in patients who have undergone resection for cure. After resection, there may be special circumstances where the need for mutation analysis may arise and these should be discussed and agreed upon at a multidisciplinary presentation. Such unusual circumstances can be accommodated by ordering the mutation analysis on the stored pathology specimen, once the need is confirmed.

Mutation analysis should be performed on all patients with non-squamous non-small cell carcinoma undergoing tissue confirmation of advanced disease or systemic failure after surgery.

This endorsement aims to eliminate the ordering and resulting costs of routine, default mutation analysis obtained after curative resection of lung cancer. In the future, this position may need to be amended if the results of ongoing clinical studies establish the use of mutation specific adjuvant therapies in patients resected for cure.

TSI Executive Committee
Jun 12, 2014

Updated:
Jun 14, 2016
Feb 26, 2018